A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE... (NCT07903415)

Title: A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.
Lead sponsor: Pfizer
Phase: Phase 1
Overall status: Recruiting
Start date: October 29, 2026
Completion date: January 26, 2032
Enrollment: 280 (estimated)
Sites: 4

carcinoma, non-small-cell lung (nsclc), esophageal cancer, gastric carcinoma, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma

A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, NON-INTERVENTIONAL, MULTI-CENTRE, POST MARKETING SURVEILLANCE (PMS) STUDY OF TALZENNA(REGISTERED) NCT04982848ObservationalWithdrawn2027
A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 2 TO LESS THAN 6 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS NCT07823595Phase 3Not yet recruiting2027
A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea. NCT07497854ObservationalNot yet recruiting2027
Post-Approval Safety Monitoring Program to Assess the Safety and Efficacy Profile of TUKYSA in Usual Practice NCT06873191ObservationalNot yet recruiting2027
AN INTERVENTIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF ATIRMOCICLIB (PF-07220060) PLUS GIREDESTRANT COMPARED TO GIREDESTRANT MONOTHERAPY AS ADJUVANT TREATMENT IN ADULT PARTICIPANTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE EARLY-STAGE BREAST CANCER WITH MEDIUM OR HIGH RISK OF RECURRENCE (FOURLIGHT-4) NCT07890597Phase 3Not yet recruiting2026

+3,329 more trials See the organization page

Outside the Cage (OTC) Robotic Esophagectomy , Single Center Phase I Trial NCT06735638Phase 1Not yet recruiting2027
A Pharmacokinetic Study of Larotinib in Subjects With Mild/Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function NCT05048368Phase 1Withdrawn2026
A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 1Recruiting2026
A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors NCT07822399Phase 1Recruiting2026
A Phase Ib Dose-Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of R01 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors, Including Squamous Cell Lung Cancer, Gastric Cancer, and Esophageal Cancer NCT07806500Phase 1Not yet recruiting2026

+251 more trials See the condition page

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.

Get the NCT07903415 report as a PDF

Registry record

Conditions

Similar trials